Pfizer, BioNTech Covid-19 vaccine on track for regulatory review in October

Pfizer Inc. and BioNTech SE said the Covid-19 vaccine they are jointly developing is on track to be submitted for regulatory review as early as October, as they released additional data from an early-stage study.

The companies said the vaccine was well tolerated with mild to moderate fever in fewer than 20% of the participants. The companies are continuing to analyze data from the Phase 1 trials in the U.S. and Germany, they said in a statement.

The confirmation of their October goal, first announced last month, helped lift S&P 500 futures early on Friday as part of a drumbeat of positive